Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a Granulocyte colony-stimulating factor (G‑CSF) presented as an injectable solution for subcutaneous use. It stimulates neutrophil production and is used to reduce the duration of neutropenia in patients receiving myelosuppressive therapy. GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Neupogen is a recombinant G‑CSF that supports the hematopoietic system in conditions associated with low neutrophil counts. - Chemotherapy‑induced neutropenia: reduces the incidence and severity of infection by accelerating neutrophil recovery. - Bone marrow transplantation: promotes engraftment and shortens the period of neutropenia after transplant. - Severe chronic neutropenia: increases absolute neutrophil count to lower infection risk. - Aplastic anemia: assists in restoring neutrophil production when bone marrow function is compromised.

Neupogen may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Bone pain: aching discomfort in the limbs or back. - Injection‑site reactions: redness, swelling, or tenderness. - Fever or chills: transient elevations in body temperature. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring urgent care. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Capillary leak syndrome: hypotension and edema. - Leukocytosis with very high neutrophil counts. - Severe bone pain unresponsive to analgesics.

Before initiating Neupogen, clinicians should assess patient‑specific factors and monitor for potential complications. - Monitor blood counts: track neutrophil recovery and avoid excessive leukocytosis. - Assess spleen size: be vigilant for splenomegaly or abdominal pain. - Use caution in sickle‑cell disease: increased risk of vaso‑occlusive events. - Avoid in patients with known hypersensitivity to filgrastim or any excipients. - Adjust therapy in renal impairment if required by the prescriber. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other agents that affect hematopoiesis or immune response.

Major Interactions (Avoid): - Concurrent use of another colony‑stimulating factor: may cause excessive neutrophil proliferation. - High‑dose chemotherapy combined with filgrastim without dose adjustment: increased risk of severe bone pain.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may blunt the neutrophil response to filgrastim. - Anticoagulants (e.g., warfarin, heparin): may increase bleeding risk at injection sites. - Monoclonal antibodies targeting immune cells: potential alteration of filgrastim efficacy. - Cytokine‑modulating agents: may affect neutrophil kinetics. - Drugs causing hypersensitivity reactions: heightened risk of allergic response.